{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Wickman E"],"funding":["Cure4Cam","National Cancer Institute","American Lebanese Syrian Associated Charities","NINDS NIH HHS","Alliance for Cancer Gene Therapy","Alex Lemonade Stand Foundation"],"pagination":["e009743"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11580246"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["12(11)"],"pubmed_abstract":["<h4>Background</h4>Oncofetal splice variants of extracellular matrix (ECM) proteins present a unique group of target antigens for the immunotherapy of pediatric cancers. However, limited data is available if these splice variants can be targeted with T cells expressing chimeric antigen receptors (CARs).<h4>Methods</h4>To determine the expression of the oncofetal version of tenascin C (TNC) encoding the C domain (C.TNC) in pediatric brain and solid tumors, we used quantitative reverse transcription PCR and immunohistochemistry. Genetically modified T cells were generated from human peripheral blood mononuclear cells and evaluated in vitro and in vivo.<h4>Results</h4>We demonstrate that C.TNC is expressed on a protein level in pediatric tumors, including diffuse intrinsic pontine glioma, ost"],"journal":["Journal for immunotherapy of cancer"],"pubmed_title":["IL-18R supported CAR T cells targeting oncofetal tenascin C for the immunotherapy of pediatric sarcoma and brain tumors."],"pmcid":["PMC11580246"],"funding_grant_id":["P30CA021765","N/A","R01NS122859","R01 NS122859","F31CA250401-01A1","1F31CA257757","R01NS121249"],"pubmed_authors":["Shaw TI","Tian L","Perry SS","Krenciute G","Zhang J","Shanmugam R","Gottschalk S","Wagner J","Chiang J","Wickman E","Koo SC","Bell M","Lu M","Sheppard H","Lange S","Ibanez J","Vogel P","Langfitt D"],"additional_accession":[]},"is_claimable":false,"name":"IL-18R supported CAR T cells targeting oncofetal tenascin C for the immunotherapy of pediatric sarcoma and brain tumors.","description":"<h4>Background</h4>Oncofetal splice variants of extracellular matrix (ECM) proteins present a unique group of target antigens for the immunotherapy of pediatric cancers. However, limited data is available if these splice variants can be targeted with T cells expressing chimeric antigen receptors (CARs).<h4>Methods</h4>To determine the expression of the oncofetal version of tenascin C (TNC) encoding the C domain (C.TNC) in pediatric brain and solid tumors, we used quantitative reverse transcription PCR and immunohistochemistry. Genetically modified T cells were generated from human peripheral blood mononuclear cells and evaluated in vitro and in vivo.<h4>Results</h4>We demonstrate that C.TNC is expressed on a protein level in pediatric tumors, including diffuse intrinsic pontine glioma, ost","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Nov","modification":"2026-06-02T04:35:24.935Z","creation":"2025-04-04T23:33:48.612Z"},"accession":"S-EPMC11580246","cross_references":{"pubmed":["39572158"],"doi":["10.1136/jitc-2024-009743"]}}